Sign in
Taking people in United StatesPhase 4

Duloxetine and celecoxib compared with placebo for knee osteoarthritis pain

Tests duloxetine, celecoxib or placebo to predict who responds, in knee osteoarthritis pain.

Key facts

Who runs it
Northwestern University
Where
Chicago, United StatesSee the site
Trial code
Registry title
Brain-Based and Clinical Phenotyping of Pain Pharmacotherapy in Knee Osteoarthritis
Status
Recruiting
Phase
Phase 4
People taking part
180 people, planned
Started
26 Feb 2024
Expected to end
15 Mar 2028
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Duloxetine
  • Celecoxib
  • Placebo
Record updated
30 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults over 40 with knee pain from knee osteoarthritis. People get duloxetine, celecoxib or placebo (a dummy tablet).

Age
Older than 40 years (from 41 Years)
Sex
Men and women
Disease stage
Knee osteoarthritis seen on X-ray. Knee pain most days for the past month. Average pain score of 4.0 or more out of 10 in the week before the start. Able to walk, with or without a cane, brace or walking stick.
Earlier treatment
No injection into the knee of hyaluronic acid or other substance in the last 6 months, or steroid in the last 90 days. No nerve ablation on the knee in the past 12 months. No high dose opioids (over 50mg morphine equivalent/day). No regular use of SSRIs, SNRIs or tricyclic antidepressants at a therapeutic dose. GLP-1 or other weight-loss treatment is allowed if started more than 3 months before screening.

Main reasons for not taking part

  • Rheumatoid arthritis, ankylosing spondylitis or other inflammatory joint disease
  • Serious heart, lung, liver or kidney disease (creatinine >1.5 mg/dl (133 µmol/L)), or past stomach ulcer or gut bleeding
  • Using a walker or wheelchair
  • Pregnant, breastfeeding or planning pregnancy
  • Cancer within 2 years, with some exceptions, or drug or alcohol abuse in the last 12 months

The registry criteria, word for word

Show all 35 criteriaShow less

Who can take part

  • Male or female, age greater than 40 years, with no racial/ethnic restrictions
  • Meet American College of Radiology criteria for knee osteoarthritis (OA) based on radiographic evidence
  • Knee pain most days of the week for the past month at screening
  • Must have average pain score for the week prior to baseline of ≥ 4.0 (on a 0 to 10 Numeric Rating Scale)
  • Must complete pain ratings on at least 4 out of 7 days prior to baseline
  • Must be able to read and speak English and be willing to read and understand instructions as well as questionnaires
  • Must be in generally stable health
  • Must be able to return for all clinic visits
  • Willing to remain stable on any concomitant therapies (Transcutaneous Electrical Nerve Stimulation (TENS) unit, ice, glucosamine chondroitin, cannabinoids, etc.)
  • Must sign an informed consent document after complete explanation of the study documenting that they understand the purpose of the study, procedures to be undertaken, possible benefits, potential risks, and are willing to participate
  • Ambulatory with or without a cane, brace(s), or walking stick (use of walker or wheelchair will be exclusionary)
  • Glucagon-like peptide 1 (GLP-1) agonists or other weight-loss treatment permitted if started more than 3 months prior to screening with no significant change in weight (+/- 11 lbs) over the past 30 days

Who cannot take part

  • Current use of illicit drugs or history (in last 12 months) of alcohol or drug abuse
  • Intra-axial implants (e.g., spinal cord stimulators or pumps)
  • Previous history of peptic ulcer or gastrointestinal bleeding
  • Recent injection into the index knee of hyaluronic acid or other substance in the last 6 months, or steroid in the last 90 days
  • Current use of selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and/or tricyclic antidepressants (TCAs) at a therapeutic dose. Occasional use of these medications as a sleep aid will be allowed; however, participants will need to agree to remain on a stable dose of the medication while in the study
  • Functional class IV congestive heart failure
  • Significant other medical disease such as uncontrolled hypertension, untreated diabetes mellitus, coronary or peripheral vascular disease, chronic obstructive lung disease, or liver disease (liver function tests > upper limit of normal)
  • Any medical condition that in the investigator's judgment may prevent the individual from completing the study or put the individual at undue risk
  • Chronic neurologic conditions, e.g., Parkinson's
  • Allergy to sulfonamide drugs, duloxetine, nonsteroidal anti-inflammatory drugs (NSAIDs), or acetaminophen
  • Acute myocardial infarction or coronary artery bypass graft surgery, in the past 12 months
  • Lactose allergy
  • Malignancy within 2 years of screening, with the exception of squamous cell carcinoma, basal cell carcinoma and prostate cancer (grade group 1)
  • Active treatment for cancer other than superficial skin cancer; or
  • Renal insufficiency (creatinine >1.5 mg/dl)
  • Current use of anticoagulants or platelet inhibitors other than aspirin at ≤325 mg/day
  • Evidence of rheumatoid arthritis, ankylosing spondylitis, other inflammatory arthropathy
  • Current cannabinoid use for knee pain
  • High dose opioid use, as defined as > 50mg morphine equivalent/day
  • In the judgment of the investigator, unable or unwilling to follow protocol and instructions
  • Currently breastfeeding, pregnant, or planning to become pregnant during the study
  • Uncontrolled narrow-angle glaucoma
  • Nerve ablation performed on the index knee within 12 months of screening

Where in United States

  • Northwestern UniversityChicago, United StatesContact: Graeme WitteTaking people

About the trial

What the trial wants to find out

This is a clinical trial of people who have pain due to knee osteoarthritis at Northwestern University Feinberg School of Medicine. The study will last for about 20 weeks. 180 qualified participants will be randomly assigned in a 1:1:1 ratio (60 participants per group) to one of three treatment groups: duloxetine, celecoxib, or placebo. Participants will have a knee Xray, (optional) MRIs of the brain and knee, blood draws, pain sensitivity testing, and asked to fill out questionnaires. The purpose of this study is to try to predict which participants will respond to the treatment.

The 3 groups in the trial

  • DuloxetineExisting treatment, for comparison

    Duloxetine 60mg tablet, daily (with an initial and final 7-day titration at 30 mg, daily)

  • CelecoxibExisting treatment, for comparison

    Celecoxib 200 mg tablet, daily

  • PlaceboPlacebo, for comparison

    Matching placebo tablet, daily

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Brain-Based and Clinical Phenotyping of Pain Pharmacotherapy in Knee Osteoarthritis
Plain-language title
Duloxetine and celecoxib compared with placebo for knee osteoarthritis painGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
30 April 2026